AR101882A1 - Métodos para preparar moduladores del receptor tipo toll - Google Patents

Métodos para preparar moduladores del receptor tipo toll

Info

Publication number
AR101882A1
AR101882A1 ARP150102954A ARP150102954A AR101882A1 AR 101882 A1 AR101882 A1 AR 101882A1 AR P150102954 A ARP150102954 A AR P150102954A AR P150102954 A ARP150102954 A AR P150102954A AR 101882 A1 AR101882 A1 AR 101882A1
Authority
AR
Argentina
Prior art keywords
compound
formula
group
alkyl
halogen
Prior art date
Application number
ARP150102954A
Other languages
English (en)
Spanish (es)
Inventor
Roethle Paul
Hrvatin Paul
L Halcomb Randall
Jade Chao Jessica
Hung Chiu Yu Richard
Yang Hong
Rudio Erwina
Mcfadden Ryan
Heath Brown Brandon
Allen Darin
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR101882A1 publication Critical patent/AR101882A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
ARP150102954A 2014-09-16 2015-09-16 Métodos para preparar moduladores del receptor tipo toll AR101882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051044P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
AR101882A1 true AR101882A1 (es) 2017-01-18

Family

ID=54291584

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102954A AR101882A1 (es) 2014-09-16 2015-09-16 Métodos para preparar moduladores del receptor tipo toll

Country Status (20)

Country Link
US (1) US9573952B2 (https=)
EP (3) EP3461828B1 (https=)
JP (4) JP6373490B2 (https=)
KR (3) KR102306860B1 (https=)
CN (2) CN115043840A (https=)
AR (1) AR101882A1 (https=)
AU (2) AU2015318062B2 (https=)
BR (1) BR112017005100A2 (https=)
CA (1) CA2960384C (https=)
EA (1) EA201790373A1 (https=)
ES (3) ES2845205T3 (https=)
IL (1) IL250849A0 (https=)
MX (1) MX2017003288A (https=)
NZ (1) NZ729526A (https=)
PL (2) PL3848375T3 (https=)
PT (2) PT3194402T (https=)
SG (1) SG11201701472VA (https=)
SI (1) SI3461828T1 (https=)
TW (2) TWI780423B (https=)
WO (1) WO2016044183A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ, インコーポレイテッド Hivを治療するためのトール様受容体の調節因子
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
TW201915000A (zh) * 2017-09-22 2019-04-16 大陸商江蘇恆瑞醫藥股份有限公司 稠合雜芳基衍生物、其製備方法及其在醫藥上的應用
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
CA3249821A1 (en) * 2022-04-26 2023-11-02 Bigelow Laboratory For Ocean Sciences PRODUCTION PROCESSES FOR HALOGENATED COMPOUNDS

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JP2886570B2 (ja) 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
JPH05320143A (ja) * 1992-03-18 1993-12-03 Mochida Pharmaceut Co Ltd 新規ピリミジン誘導体
TW274550B (https=) 1992-09-26 1996-04-21 Hoechst Ag
EP0743855A1 (en) 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
BR9710808A (pt) 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
US5693641A (en) 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
WO2000000478A1 (en) 1998-06-26 2000-01-06 Bristol-Myers Squibb Pharma Company Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US7169778B2 (en) 1999-09-15 2007-01-30 Warner-Lambert Company Pteridinones as kinase inhibitors
US6452325B1 (en) 2000-07-24 2002-09-17 Thermoplastic Processes, Inc. Shatterproofing of fluorescent lamps
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
UA76512C2 (en) 2001-09-04 2006-08-15 Boehringer Ingelheim Pharma Dihydropteridinones, a method for producing thereof and use thereof as medicament
JP3876265B2 (ja) 2003-02-26 2007-01-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ジヒドロプテリジノン、その製造方法及び薬物形態での使用
EP2269638A3 (en) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
CA2617589A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
EP2657235A1 (en) * 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2007103554A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
EP2004193A2 (en) 2006-03-13 2008-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2009541284A (ja) 2006-06-23 2009-11-26 アストラゼネカ・アクチエボラーグ プテリジン誘導体およびカテプシン阻害剤としてのそれらの使用
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
AR065372A1 (es) 2007-02-19 2009-06-03 Smithkline Beecham Corp Derivados de purina
AU2008228303B2 (en) 2007-03-22 2012-04-19 Takeda Pharmaceutical Company Limited Substituted pyrimidodiazepines useful as PLK1 inhibitors
KR20120003499A (ko) * 2007-04-05 2012-01-10 지멘스 메디컬 솔루션즈 유에스에이, 인크. 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조
US20100179109A1 (en) * 2007-04-05 2010-07-15 Baldwin Jonh J Renin inhibitors
ES2441196T3 (es) * 2007-04-18 2014-02-03 Kissei Pharmaceutical Co., Ltd. Derivado de anillo condensado nitrogenado, composiciones farmacéuticas que lo contienen, y su uso con fines médicos
AU2008287339A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
WO2009022185A2 (en) 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
US20090291938A1 (en) 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CN101284810A (zh) * 2008-06-02 2008-10-15 秦引林 氰基吡咯烷和氰基噻唑烷衍生物
RS53347B (sr) * 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
CA2772253C (en) * 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
US20130273005A1 (en) * 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv

Also Published As

Publication number Publication date
TWI692468B (zh) 2020-05-01
SI3461828T1 (sl) 2021-01-29
EP3194402B1 (en) 2018-11-21
KR20210118985A (ko) 2021-10-01
KR101978809B1 (ko) 2019-05-15
US20160075707A1 (en) 2016-03-17
ES2845205T3 (es) 2021-07-26
TWI780423B (zh) 2022-10-11
US9573952B2 (en) 2017-02-21
SG11201701472VA (en) 2017-04-27
JP2019214626A (ja) 2019-12-19
PT3461828T (pt) 2021-01-26
AU2015318062A1 (en) 2017-03-16
AU2018236824B2 (en) 2020-04-23
CN107074860A (zh) 2017-08-18
AU2015318062B2 (en) 2018-07-05
KR102306860B1 (ko) 2021-09-30
EA201790373A1 (ru) 2017-08-31
JP6596127B2 (ja) 2019-10-23
CA2960384C (en) 2019-07-23
JP7333843B2 (ja) 2023-08-25
ES2975520T3 (es) 2024-07-08
JP7063865B2 (ja) 2022-05-09
ES2706527T3 (es) 2019-03-29
PL3848375T3 (pl) 2024-05-06
EP3848375B1 (en) 2023-12-27
NZ729526A (en) 2018-05-25
MX2017003288A (es) 2017-06-28
CN107074860B (zh) 2022-07-15
KR20170048592A (ko) 2017-05-08
EP3848375C0 (en) 2023-12-27
JP2022051834A (ja) 2022-04-01
KR102457426B1 (ko) 2022-10-24
EP3461828B1 (en) 2020-11-25
EP3194402A1 (en) 2017-07-26
WO2016044183A1 (en) 2016-03-24
CN115043840A (zh) 2022-09-13
JP6373490B2 (ja) 2018-08-15
PT3194402T (pt) 2019-02-11
EP3461828A2 (en) 2019-04-03
TW201625524A (zh) 2016-07-16
TW202043195A (zh) 2020-12-01
KR20190053292A (ko) 2019-05-17
EP3461828A3 (en) 2019-05-01
IL250849A0 (en) 2017-04-30
JP2017526729A (ja) 2017-09-14
JP2018158953A (ja) 2018-10-11
BR112017005100A2 (pt) 2017-12-05
AU2018236824A1 (en) 2018-10-18
EP3848375A1 (en) 2021-07-14
PL3461828T3 (pl) 2021-07-19
CA2960384A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
AR101882A1 (es) Métodos para preparar moduladores del receptor tipo toll
CL2020001546A1 (es) Compuestos de 4-azaindol.
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
CU24466B1 (es) Compuestos derivados de d-fenilalanina-n-sustituido con biciclos aromáticos, método de preparación de las mismas y composiciones farmacéuticas que los contienen
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
CU20180146A7 (es) Compuestos derivados de (piperidin-1-ilo)(piperidin-4-ilo) sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen
ES2684517T3 (es) Compuestos de heterociclilo como inhibidores de MEK
MX2018005132A (es) Agonistas del receptor de glucagon.
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
UY36735A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2018007996A (es) Composiciones de decil mercaptanos mezclados y uso de las mismas como colectoras de productos quimicos de mineria.
AR099995A1 (es) Piridilamidinas fungicidas
PE20211002A1 (es) Compuestos como moduladores de ror gamma
EP3583400A4 (en) TEST PROCEDURE FOR HYDROGEN EMBRIDITY
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
CL2017001336A1 (es) Nuevos aminoácidos ester fosforamidatos 2' y/o 5', 3' deoxiadenosina derivativos como compuestos anticancerígenos
CL2017000818A1 (es) Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii
AR092170A1 (es) Proceso para la fabricacion de benzoxazinonas
AR103192A1 (es) Isotiazolamidas, procesos para su preparación y su uso como herbicidas y/o reguladores del crecimiento vegetal
MX2016016050A (es) Procesos para la preparacion de analogos de oxitocina.
AR100876A1 (es) Métodos para producir arenos borilados
PE20190778A1 (es) Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida
MX381350B (es) Proceso para la preparacion de 1,4-bis (etoximetil) ciclohexano.

Legal Events

Date Code Title Description
FB Suspension of granting procedure